الفهرس 
List of contentsOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
DLBCL is the most common NHL in adults (40%) and third common in pediatrics (20%) following lymphoblastic lymphoma and BL. It is a heterogeneous disease with different clinical features, histologic subtypes, immunophenotypic profiles, molecular features and response to standard therapy. So, the identification of the risk groups is important to guide appropriate protocols of therapy and identify new potential therapeutic targets. GEP divided DLBCL according to the COO and the deregulated molecular pathways into GCB, ABC and third subtypes. Further studies found that GCB DLBCL has better prognosis than the other subtypes. Several clinical trials are attempting to tailor the treatment of the ABC subtype using specific target drug therapy. The WHO 2016 classification of hematopoietic and lymphoid malignancies uses the Hans algorithm for classification of DLBCL into GCB and non-GCB using IHC for CD10, Bcl-6 and MUM1. It was considered as alternative for GEP with about 86% accuracy. Five different IHC profiles are classified as GCB and three different profiles are classified as non-GCB. This retrospective study was carried out on 100 cases of de novo DLBCL diagnosed at the surgical pathology laboratory, OCMU center during the period from January 2011 to December 2014. All patients underwent surgical resection. The study is conducted using four constructed TMA paraffin blocks. H&E-stained slides were examined to assess the histological variants. IHC for CD10, bcl-6 and MUM1 was done and the cases were classified as GCB/non-GCB according to Hans algorithm. Also we study the prognostic implications of GCB/non-GCB subtypes with the effect of the various IHC profiles on the survival. This study showed that there is no significant relation between the histological variants and GCB/non-GCB IHC subtypes. GCB DLBCL was associated with better DFS and OS than the non-GCB DLBCL (DFS, 40 months versus 18 months, OS, 67 versus 54 months). GCB DLBCL subgroup expressing both CD10 and MUM1 had the shortest DFS (6 months) among the GCB subgroups. GCB subgroup expressing CD10, Bcl-6 and MUM1 showed DFS 35 months which was comparable to other GCB subgroups. This indicates that Bcl-6 is a good prognostic factors, however, MUM1 is associated with worse prognosis. Non-GCB DLBCL subgroup which did not express CD10, Bcl-6 and MUM1 had the longest DFS (29 month) among the other non-GCB subgroups. No significant difference in the OS was observed among these subgroups.